379 related articles for article (PubMed ID: 24244833)
1. The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.
Johnson R; Sabnis N; McConathy WJ; Lacko AG
Pharmaceutics; 2013; 5(2):353-70. PubMed ID: 24244833
[TBL] [Abstract][Full Text] [Related]
2. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
3. Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review.
Maqbool M; Bekele F; Fekadu G
Breast Cancer (Dove Med Press); 2022; 14():15-24. PubMed ID: 35046722
[TBL] [Abstract][Full Text] [Related]
4. Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.
Mendes TF; Kluskens LD; Rodrigues LR
Adv Sci (Weinh); 2015 Nov; 2(11):1500053. PubMed ID: 27980912
[TBL] [Abstract][Full Text] [Related]
5. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.
Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ
Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer.
Ensenyat-Mendez M; Llinàs-Arias P; Orozco JIJ; Íñiguez-Muñoz S; Salomon MP; Sesé B; DiNome ML; Marzese DM
Front Oncol; 2021; 11():681476. PubMed ID: 34221999
[TBL] [Abstract][Full Text] [Related]
8. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
Tong L; Yu X; Wang S; Chen L; Wu Y
Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
[TBL] [Abstract][Full Text] [Related]
9. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
Li Y; Zhan Z; Yin X; Fu S; Deng X
Front Oncol; 2021; 11():731535. PubMed ID: 34778045
[TBL] [Abstract][Full Text] [Related]
11. Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
Saha P; Nanda R
Ther Adv Med Oncol; 2016 Sep; 8(5):351-9. PubMed ID: 27583027
[TBL] [Abstract][Full Text] [Related]
12. Targeting triple negative breast cancer stem cells using nanocarriers.
Dasari N; Guntuku GS; Pindiprolu SKSS
Discov Nano; 2024 Mar; 19(1):41. PubMed ID: 38453756
[TBL] [Abstract][Full Text] [Related]
13. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
Yoder R; Kimler BF; Staley JM; Schwensen K; Wang YY; Finke K; O'Dea A; Nye L; Elia M; Crane G; McKittrick R; Pluenneke R; Madhusudhana S; Beck L; Shrestha A; Corum L; Marsico M; Stecklein SR; Godwin AK; Khan QJ; Sharma P
NPJ Breast Cancer; 2022 Jul; 8(1):80. PubMed ID: 35817765
[TBL] [Abstract][Full Text] [Related]
14. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: disease entity or title of convenience?
Carey L; Winer E; Viale G; Cameron D; Gianni L
Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapies for metastatic triple-negative breast cancer.
Bayraktar S; Glück S
Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
[TBL] [Abstract][Full Text] [Related]
20. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook.
Obidiro O; Battogtokh G; Akala EO
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37513983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
